SA
Go ProLog In
RGNX
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
20 analysts·High coverage
68
Score
14 Buy (70%)5 Hold (25%)1 Sell (5%)
Rating Breakdown
Strong Buy
15%
Buy
1365%
Hold
525%
Sell
15%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$12.00
+109.8%
Consensus
$19.00
+232.2%
Bull
$45.00
+686.7%
12-Month Target Range20 analysts
$12.00$19.00$45.00
Current $5.72Consensus
Current Price
$5.72
Upside to Consensus
$13.28

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+14.00%
EPS—
FY2028
Rev+58.07%
EPS—
FY2029
Rev+53.58%
EPS—

Earnings Surprises

Recent Analyst Actions

May 15, 2026Morgan Stanley
Regenxbio price target lowered to $16 from $17 at Morgan Stanley
Target:$16.00
+153.6%from $6.31
May 15, 2026Barclays
Regenxbio price target lowered to $12 from $37 at Barclays
Target:$12.00
+92.2%from $6.25
Mar 9, 2026H.C. Wainwright
Regenxbio price target lowered to $30 from $32 at H.C. Wainwright
Target:$30.00
+189.0%from $10.38
Mar 5, 2026Morgan Stanley
Regenxbio Inc. (RGNX) PT Lowered to $17 at Morgan Stanley
Target:$17.00
+95.0%from $8.72
Feb 10, 2026H.C. Wainwright
Regenxbio price target lowered to $32 from $34 at H.C. Wainwright
Target:$32.00
+258.9%from $8.91
Feb 10, 2026Robert W. Baird
Regenxbio price target lowered to $27 from $39 at Baird
Target:$27.00
+202.7%from $8.92
Feb 10, 2026UBS
Regenxbio price target lowered to $18 from $25 at Morgan Stanley
Target:$18.00
+100.8%from $8.96
Feb 10, 2026Goldman Sachs
Regenxbio price target lowered to $12 from $14 at Goldman Sachs
Target:$12.00
+16.4%from $10.31
Jan 29, 2026H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
Target:$34.00
+195.1%from $11.52
Jan 27, 2026Barclays
Regenxbio assumed with an Overweight at Barclays
Target:$37.00
+175.9%from $13.41
Dec 19, 2025Stifel Nicolaus
Regenxbio price target raised to $45 from $40 at Stifel
Target:$45.00
+233.1%from $13.51
Dec 15, 2025Leerink Partners
Regenxbio Inc. (RGNX) PT Raised to $20 at Leerink Partners
Target:$20.00
+44.1%from $13.88
Mar 18, 2025Leerink Partners
Sarepta news opens door for Regenxbio over risk/benefit profile, says Leerink
Target:$24.00
+207.7%from $7.80
Jan 7, 2025RBC Capital
Regenxbio price target lowered to $30 from $35 at RBC Capital
Target:$30.00
+258.9%from $8.36
Nov 15, 2024Morgan Stanley
Morgan Stanley Assumes Regenxbio Inc. (RGNX) at Overweight
Target:$22.00
+97.5%from $11.14
Oct 10, 2024Raymond James
Regenxbio reinstated with an Outperform at Raymond James
Target:$18.00
+96.0%from $9.19
Sep 5, 2024H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
Target:$39.00
+242.9%from $11.38
Jun 24, 2024Stifel Nicolaus
Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)
Target:$40.00
+212.7%from $12.79
Jun 7, 2024Goldman Sachs
Goldman Sachs Starts Regenxbio Inc. (RGNX) at Buy
Target:$38.00
+176.2%from $13.76
May 15, 2024H.C. Wainwright
Regenxbio price target raised to $38 from $36 at H.C. Wainwright
Target:$38.00
+140.5%from $15.80
Mar 11, 2024H.C. Wainwright
H.C. Wainwright Starts Regenxbio Inc. (RGNX) at Buy; 'Advancing Gene Therapies in Ophthalmology and Rare Diseases'
Target:$36.00
+57.5%from $22.85
Mar 8, 2024RBC Capital
RBC Capital Upgrades Regenxbio Inc. (RGNX) to Outperform
Target:$35.00
+53.8%from $22.75

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance